Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.62 |
| ▸ | HPN | P05981 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SDCBP | O00560 | 1/20 | 0.46 |
| ▸ | SDC2 | P34741 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2572109 | 0.91 | HDAC1 (0.52) | HDAC1NAMPTGAANQO2CTSS | |
| SCHEMBL3278182 | 0.87 | NQO2 (0.56) | HDAC1NAMPTNQO2CTSSCTSK | |
| SCHEMBL2568359 | 0.87 | HDAC1 (0.56) | HDAC1HPNNQO2CTSSCTSK | |
| SCHEMBL2567630 | 0.86 | HDAC1 (0.57) | HDAC1HPNNAMPTGAAL3MBTL1 | |
| SCHEMBL1691047 | 0.86 | HDAC1 (0.67) | HDAC1NAMPTGAAL3MBTL1SDCBP | |
| SCHEMBL31716389 | 0.86 | HDAC1 (0.58) | HDAC1HPNNAMPTGAAL3MBTL1 | |
| SCHEMBL3278301 | 0.86 | HDAC1 (0.58) | HDAC1HPNNAMPTGAAL3MBTL1 | |
| SCHEMBL30151702 | 0.85 | GLS (0.52) | HDAC1NAMPTGAANQO2CYP3A4 | |
| SCHEMBL1111369 | 0.85 | GLS (0.52) | HDAC1NAMPTGAANQO2CYP3A4 | |
| SCHEMBL30504293 | 0.85 | HDAC1 (0.56) | HDAC1NAMPTCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3349581-B1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10766890-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| WO-2017048962-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7795236-B2 | Purine nucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-7700605-B2 | 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080214548-A1 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors | FLOHR STEFANIE | 2008-09-04 | — | — | US | disclosed |
| EP-1907368-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007009715-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | NUDT1, PNP, SLC28A2 | HDAC1 2556/4885HPN 920/4885NAMPT 45/4885 |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | NUDT1, SLC28A2, PNP | HDAC1 2720/4885HPN 842/4885NAMPT 81/4885 |
| US-20080214548-A1 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors | USP2, UCHL3, UCHL5 | HDAC1 1790/4885HPN 494/4885NAMPT 2605/4885 |
| US-10766890-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | HDAC1 2819/4885HPN 113/4885NAMPT 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.